China SXT Pharmaceuticals, Inc. (SXTC)
↓ Download CSV- Sector Manufacturing
- Incorporated D8
- Fiscal year ends Mar 31
In fiscal 2025, China SXT Pharmaceuticals, Inc. reported revenue of $1.74M, down 9.7% from the prior year. The company ran a net loss, with a net margin of -189.8% and a gross margin of 21.1%. It held $21.66M in total assets against $6.22M in total liabilities.
Key ratios (FY2025)
21.1%
Gross margin
-154.0%
Operating margin
-189.8%
Net margin
-21.4%
Return on equity
-9.7%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.74M | $1.93M | $1.97M | — | — | — | — | — | — | — |
| Cost of Revenue | $1.37M | $1.37M | $1.55M | $1.35M | $1.94M | $2.46M | $2.40M | $3.62M | $2.57M | — |
| Gross Profit | $367.4K | $554.0K | $426.3K | $1.25M | $2.84M | $2.70M | $4.61M | $3.40M | $2.31M | — |
| Operating Income | -$2.68M | -$2.52M | -$5.61M | -$5.19M | -$2.20M | -$1.34M | $1.77M | $1.63M | $1.60M | — |
| Net Income | -$3.30M | -$3.10M | -$5.93M | -$5.74M | -$2.75M | -$10.29M | $1.54M | $1.19M | $1.19M | — |
| EPS (Diluted) | $-2.32 | $-28.58 | $-177.84 | $-137.92 | $-3.82 | $33.28 | $0.07 | $0.06 | $0.06 | — |
| Total Assets | $21.66M | $23.13M | $29.55M | $33.55M | $34.55M | $21.70M | $17.47M | $7.66M | — | — |
| Total Liabilities | $6.22M | $9.20M | $14.86M | $17.12M | $18.59M | $12.30M | $6.36M | $4.37M | — | — |
| Shareholders' Equity | $15.44M | $13.93M | $14.69M | $16.08M | $15.96M | $9.40M | $11.11M | $3.29M | $1.85M | $742.8K |
| Cash & Equivalents | $18.10M | $12.07M | $17.37M | — | $13.36M | $7.29M | $9.29M | $657.8K | $65.6K | $11.4K |
| Operating Cash Flow | -$2.35M | -$1.93M | -$80.8K | $268.3K | -$1.32M | $934.2K | $239.2K | $1.92M | $293.0K | — |
| Capital Expenditures | — | — | — | — | — | $130.8K | $535.8K | $436.0K | $179.2K | — |
| Shares Outstanding | 13.76M | 13.76M | 457.4K | 2.03M | 776.3K | 8.67M | 22.71M | 20.00M | — | — |